

Food and Drug Administration Advisory Committee Member Acknowledgment of Financial Interests

Name of Advisory Committee Member: Steven DuBois, M.D.

Committee: Pediatric Subcommittee of the Oncologic Drugs Advisory Committee

Meeting Date: June 28-29, 2016

I acknowledge that contingent upon public disclosure of the following financial interest(s) related to the agenda item: At the advisory committee meeting, information will be presented to gauge investigator interest in exploring potential pediatric development plans for five chemical entities including, tazometostat, atezolizumab, and entrectinib, I may be considered for participation in the advisory committee meeting described above.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
I. Personal/Immediate Family		
Consultant/Advisor	(b) (6), potentially affected firm	(b) (6) per year
II. Other Imputed Interests		
Contract/Grant	Two interests with Epizyme, sponsor	\$100,001 – 300,000 per year, per interest
	Roche, sponsor	\$50,001 – 100,000 per year
	Ignyta, sponsor	\$0 – 50,000 per year
	Loxo Oncology, potentially affected firm	\$0 – 50,000 per year

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the sessions described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee sessions described above.

/s/
Signature

6/27/16
Date